

IN THE SPECIFICATION:

Please amend the specification as follows:

On page 2, line 7, please insert a comma “,” between “parasitic infections” and “urinary or fecal incontinence”.

On page 9, lines 11 and 12, change “US patent applications no. 2003017207 and 2003064103” to --U.S. patent applications no. 20030017207 and 20030064103--.

On page 19, line 9, change “fluconazole-ticonazole association” to --fluconazole-tinidazole association--.

On page 19, line 11, in the paragraph immediately following ‘Example 1’ of the ‘Examples of composition’, please replace the existing table with the marked up table below:

<u>Ingredient</u>	<u>Quantity</u>	<u>% by Weight</u>
Tinidazole	500 mg	<u>75%</u>
Fluconazole	37.5 mg	<u>5.7%</u>
Microcrystalline Cellulose 101	60.50 mg	<u>9.2%</u>
Sodium glycolate of starch	6.50 mg	<u>0.98%</u>
Crospovidone	16.25 mg	<u>2.4%</u>
Lauril sodium sulfate	6.50 mg	<u>0.98%</u>
Polyvinylpirrolidone K-30	19.5 mg	<u>3.0%</u>
Magnesium stearate	3.25 mg	<u>0.49%</u>
White Opadry YS 7322	10.5 mg	<u>1.6%</u>
Total	660.5 mg	

On page 20, line 2, change “fluconazole-ticonazole association” to --fluconazole-tinidazole association--.

On page 20, line 4, in the paragraph immediately following ‘Example 2’ of the ‘Examples of composition’, please replace the existing table with the marked up table below:

Ingredient	Quantity	% by Weight
Tinidazole	750 mg	75%
Fluconazole	56.25 mg	<u>5.7%</u>
Microcrystalline Cellulose 101	90.75 mg	<u>9.2%</u>
Sodium glycolate of starch	9.75 mg	<u>0.98%</u>
Crospovidone	24.37 mg	<u>2.5%</u>
Lauril sodium sulfate	9.75 mg	<u>0.98%</u>
Polyvinylpyrrolidone K-30	29.25 mg	<u>3.0%</u>
Magnesium stearate	4.87 mg	<u>0.49%</u>
White Opadry YS 7322	15.75 mg	<u>1.6%</u>
Total	1321 mg <u>990.74 mg</u>	

On page 20, line 2, change “fluconazole-ticonazole association” to --fluconazole-tinidazole association--.

On page 20, line 9, in the paragraph immediately following 'Example 3' of the 'Examples of composition', please replace the existing table bridging page 20 and 21 with the marked up table below:

Ingredient	Quantity	% by Weight
Tinidazole	1500 mg	<u>75%</u>
Fluconazole	112.5 mg	<u>5.7%</u>
Microcrystalline Cellulose 101	181.5 mg	<u>9.2%</u>
Sodium glycolate of starch	18.15 mg	<u>0.92%</u>
Crospovidone	48.75 mg	<u>2.5%</u>
Lauril sodium sulfate	19.5 mg	<u>0.98%</u>
Polyvinylpyrrolidone K-30	58.5 mg	<u>3.0%</u>
Magnesium stearate	9.75 mg	<u>0.49%</u>
White Opadry YS 7322	31.5 mg	<u>1.6%</u>
Total	<u>1981.5 mg</u> <u>1980.2 mg</u>	

On page 21, line 7, in the paragraph immediately following ‘Example 4’ of the ‘Examples of composition’, please replace the existing table bridging page 21 and 22 with the marked up table below:

<u>Ingredient</u>	<u>Quantity</u>	<u>% by Weight</u>
Secnidazole	500 mg	75%
Fluconazole	37.5 mg	5.7%
Microcrysytalline Cellulose 101	60.50 mg	9.2%
Sodium glycolate of starch	6.50 mg	0.98%
Crospovidone	16.25 mg	2.5%
Lauril sodium sulfate	6.50 mg	0.98%
Polyvinylpyrrolidone K-30	19.5 mg	3.0%
Magnesium stearate	3.25 mg	0.49%
White Opadry YS 7322	10.5 mg	1.6%
Total	660.5 mg	

On page 29, line 6 of the Abstract, change “either tinidazole is used” to --either tinidazole or secnidazole is used--.